Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 14Neoplasms 10Thoracic Neoplasms 3Carcinoma 3Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2NSCLC 2Meningeal Carcinomatosis 2Lung Diseases 2Colorectal Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Solid Tumor, Adult 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Lethal Congenital Contracture Syndrome 2 1Hemangioendothelioma, Epithelioid 1Head and Neck Neoplasms 1

Interventions

Paclitaxel 2Kidney Transplantation 2Cyclophosphamide 2Azacitidine 2veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pomalidomide 1pevonedistat 1osimertinib 1mirabegron 1glucarpidase 1gamma-Glutamyl Hydrolase 1dabrafenib 1copanlisib 1belinostat 1belantamab mafodotin 1Whole-Body Irradiation 1Topotecan 1Taxes 1Sitagliptin Phosphate 1Rituximab 1Pharmacogenomic Testing 1Oxaliplatin 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Renal Insufficiency × osimertinib × Clear all
NCT02923947 2023-11-27

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

AstraZeneca

Phase 1 Completed
16 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡